Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
ANTI-GPC3 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2021/110095
Kind Code:
A1
Abstract:
Provided are a chimeric antibody and humanized antibody of the CDR regions of an anti-GPC3 antibody; also provided are a pharmaceutical composition containing an anti-GPC3 antibody or an antigen-binding fragment thereof, and a use thereof as an anti-cancer drug.

Inventors:
HUA HAIQING (CN)
YU HUAXING (CN)
HE JUANMEI (CN)
BAO RUDI (CN)
Application Number:
PCT/CN2020/133588
Publication Date:
June 10, 2021
Filing Date:
December 03, 2020
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
SHANGHAI HANSOH BIOMEDICAL CO LTD (CN)
JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD (CN)
International Classes:
C07K16/30; A61K39/395; C07K14/705; C12N15/13
Domestic Patent References:
WO2017020812A12017-02-09
Foreign References:
CN105820249A2016-08-03
CN109021108A2018-12-18
CN104610441A2015-05-13
CN110177876A2019-08-27
Other References:
YI-FAN ZHANG, MITCHELL HO: "Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma", SCIENTIFIC REPORTS, vol. 6, no. 1, 1 December 2016 (2016-12-01), XP055544227, DOI: 10.1038/srep33878
NAKANO KIYOTAKA; ISHIGURO TAKAHIRO; KONISHI HIROKO; TANAKA MEGUMI; SUGIMOTO MASAMICHI; SUGO IZUMI; IGAWA TOMOYUKI; TSUNODA HIROYUK: "Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization", ANTI-CANCER DRUGS, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 21, no. 10, 1 November 2010 (2010-11-01), US, pages 907 - 916, XP008177208, ISSN: 0959-4973, DOI: 10.1097/CAD.0b013e32833f5d68
Attorney, Agent or Firm:
GE CHENG & CO., LTD (CN)
Download PDF: